Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs

A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs

Thumbnail Image
Download
Name

Kamm_A quantitative microfluidic.pdf

Size

1.14 MB

Format

Adobe PDF

Checksum (MD5)

86449263987c80f7f6bead25b5d46853

Author(s)
Kim, Choong
•
Kasuya, Junichi
•
Jeon, Jessie S
•
Chung, Seok
•
Kamm, Roger Dale
Date Issued
November 2014
Journal
Lab Chip
Publisher
Royal Society of Chemistry (Great Britain)
Citation
Kim, Choong, Junichi Kasuya, Jessie Jeon, Seok Chung, and Roger D. Kamm. “A Quantitative Microfluidic Angiogenesis Screen for Studying Anti-Angiogenic Therapeutic Drugs.” Lab Chip 15, no. 1 (2015): 301–310. doi:10.1039/c4lc00866a.
Version
Author's final manuscript
Abstract
Anti-angiogenic therapy, which suppresses tumor growth by disrupting oxygen and nutrient supply from blood to the tumor, is now widely accepted as a treatment for cancer. To investigate the mechanisms of action of these anti-angiogenesis drugs, new three dimensional (3D) cell culture-based drug screening models are increasingly employed. However, there is no in vitro high-throughput screening (HTS) angiogenesis assay that can provide uniform culture conditions for the quantitative assessment of physiological responses to chemoattractant reagents under various concentrations of anti-angiogenesis drugs. Here we describe a method for screening and quantifying the vascular endothelial growth factor (VEGF)-induced chemotactic response on human umbilical vein endothelial cells (HUVECs) cultured with different concentrations of bortezomib, a selective 26S proteasome inhibitor. With this quantitative microfluidic angiogenesis screen (QMAS), we demonstrate that bortezomib-induced endothelial cell death is preceded by a series of morphological changes that develop over several days. We also explore the mechanisms by which bortezomib can inhibit angiogenesis.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Singapore-MIT Alliance in Research and Technology (SMART)
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/107403
DOI of Published Version
https://doi.org/10.1039/c4lc00866a
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.